Treatment of bacterial lipopolysaccharides (endotoxins) isolated from Salmonella minnesota R595 or purified lipid A with the antibiotic polymyxin B has been demonstrated to abrogate the ability of these molecules to activate serum complement. The inhibition is a function of the ratio of polymyxin B to lipopolysaccharide.
The addition of the polypeptide antibiotic polymyxin B to preparations of bacterial lipopolysaccharides (LPS) has been shown to drastically alter many ofthe in vivo deleterious pathophysiological effects of LPS. Rifkind and co-workers first demonstrated that several cyclic polypeptide antibiotics had the capacity to neutralize the toxicity of endotoxin in chicken embryos (16) and in adrenalectomized mice (14) . Further studies by these authors demonstrated that polymyxin B could prevent the generalized Shwartzman reaction in rabbits when either the provocative or the preparatory dose of LPS was treated with polymyxin B (15) . Similar studies by Corrigan and Bell showed that administration of polymyxin B simultaneously with the second injection of LPS or mixed with LPS in vitro prior to the second injection prevented disseminated intravascular coagulation and bilateral renal cortical necrosis (3 Preparations of LPS (9) and, in particular, the lipid A region of LPS (5) have been demonstrated to be potent activators of serum complement. Since the complement system constitutes one of the principal mediator systems present in serum (11) , it may contribute substantially to many of the in vivo effects of LPS. We have, therefore, examined the effect of polymyxin B on the anticomplementary activity of LPS. Although the precise role of complement in the generation of LPS-initiated pathophysiological 298 changes is, at present, not well understood, the participation of complement components in lethality to rabbits (7), hypotensive changes in dogs (6) , and complement and circulating platelet changes in rabbits (1) has been demonstrated with several preparations of LPS. In this report we demonstrate that polymyxin B abrogates the ability of LPS and lipid A to activate serum complement. These data would thus support the concept of a potential role for complement in LPS-mediated host injury.
LPS from Escherichia coli 0111:B4 was extracted by the phenol-water procedure of Westphal and Jann (18) and purified by gel filtration chromatography (10) . LPS from the rough mutant R595 was extracted and purified by the procedure of Galanos et al. (4) . (The R595 LPS from Salmonella minnesota and the lipid A from Salmonella typhimurium R60 were prepared while D.C.M. was a guest in the laboratory of Otto Luderitz, Max Planck Institut ftir Immunobiologie, Freiburg, West Germany.) A purified preparation of lipid A was obtained after mild acid hydrolysis of a phenolwater extract of S. typhimurium R60. Polymyxin B sulfate and inulin were obtained from Sigma Chemical Co., St. Louis, Mo. The anticomplementary protein from cobra venom (CoF) was prepared by diethylaminoethyl-Sephadex chromatography as described elsewhere (2) . To determine activation of serum complement, samples of LPS in 100 ,ul of veronal buffer (pH 7.4) were incubated with 500 ,ul of a 1:12 dilution of normal rabbit serum at 37 C. Then, 400 ,ul of sensitized sheep erythrocytes (5 x 108 cells/ml) was added, and incubation was continued for an additional 30 to 40 min. Cells were then diluted with 2 ml of ice-cold saline and centrifuged, and absorbance of supernatants was measured at 541 nm.
Preparations of LPS as well as isolated lipid A were examined for their ability to activate serum complement both before and after treatment with an equal weight of polymyxin B. Treatment of the highly active, complementactivating LPS preparation from S. minnesota R595, as well as purified lipid A, with polymyxin B completely abrogates the ability of these preparations to inactivate complement (Fig. 1) . Whereas as little as 0.8 ,ug of R595 LPS yields a 50% inhibition of the hemolytic activity of rabbit complement, 100 ug of the LPS-polymyxin B is completely ineffective. A similar effect is demonstrated with lipid A preparations. As a control, the noncomplement-activating LPS from E. coli 0111:B4 is unaltered by formation of a complex with polymyxin B. Further, none of the preparations of LPS or LPS treated with polymyxin B had any demonstra- 
. Inhibition of hemolysis by LPS and LPSpolymyxin B. Samples ofLPS or lipid A were treated
with an equal weight ofpolymyxin B in a final volume of100 pl. Control samples were treated without polymyxin B. Then, 5()0 p of a 1:12 dilution of normal rabbit serum was added, and samples were incubated for 30 min at 37 C, after which 400 g of sensitized sheep erythrocytes (5 x 108 cellslml) was added and incubation was continued for an additional 30 to 45 min. All samples were then diluted with 2 ml of ice-cold saline and centrifuged, and absorbance of supernatants was measured at 541 nm. Results are expressed as percentage of inhibition of hemolysis and are calculated from control samples without LPS. Control samples gave 75 to 80% hemolysis. ble effect on sensitized sheep erythrocytes in the absence of rabbit serum.
To examine the minimal amount of polymyxin B required to inhibit the activation of complement by LPS, decreasing amounts ofpolymyxin B were added to either 2.5 or 5.0 ,Mg of R595 LPS. These samples were then assessed for the capability to inhibit hemolysis, as described above. The results of this experiment (Fig. 2) demonstrate that approximately 0.8 tg of polymyxin B is required to yield a 50% inhibition ofthe activation of complement by 2.5 ,ug of R595 LPS. When the amount of LPS is increased to 5 ,ug, the amount of polymyxin B required to yield equivalent inhibition is similarly increased to 2 Mg. These data would suggest that the polymyxin B is interacting primarily with the LPS, even in the presence of normal serum. The fact that complete hemolysis of the sensitized erythrocytes may be obtained in the presence of polymyxin B would indicate that this latter molecule has no effect on complement components involved in the classical activation pathway. However, as LPS has recently been demonstrated to activate both the classical and alternative (Properdin) pathways (17) , it was important to demonstrate that the presence of polymyxin had no effect on alternate pathway components. To this end, various concentrations of polymyxin were examined for their ability to inhibit inulin and CoF activation of serum complement. Polymyxin B was markedly less effective as an inhibitor of either inulin or CoF as compared with LPS (Fig. 2) . Greater than a 50-fold excess of polymyxin B is required to give minimal inhibition of complement activation by CoF as compared with an equivalent amount of LPS. The activation of complement by inulin was also minimally affected by the presence of polymyxin over the concentration range tested. It was necessary to use the rather high concentration of inulin (100 jig) since concentrations less than this did not give sufficient inactivation of complement. In spite of this, whereas an equal weight of polymyxin B, in both instances, abrogated LPS activity, equivalent concentration ratios had absolutely no effect on inulin activity.
Thus, the interaction between polymyxin B and LPS abrogates the ability of LPS to acti- 
